About US
Contact us
-
CFDA Commissioner Zhang Yong meets the delegation of Swedish Ministry of Health and Social AffairsOn the morning of April 16, 2013, Zhang Yong, Commissioner of China Food and Drug Administration (CFDA), met with the delegation led by Mr. Goran Hagglund, the Swedish Minister for Health and Social2013/4/16
-
2013 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 2nd station--Xian was successfully concluded2013 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 2nd station--Xian , was successfully concluded on 11 April at Xian Enlite Hotel. Around 100 technical persons from 26 pha2013/4/15
-
Roche CEO says no need to buy out Japanese subsidiary ChugaiWhen it comes to its investment in Japan's Chugai Pharmaceutical, Roche CEO Severin Schwan says he likes things just the way they are. "We don't see changes in the structural set-up ... currency fluct2013/4/15
-
Pfizer cuts physician payments by about $17M in 2012It's not that there is no free lunch for doctors, there are just fewer of them. Some members of Big Pharma are significantly cutting their budgets for spending on docs as lost sales and resulting d2013/4/15
-
Pfizer Ventures backs effort to amp up orphan-drug developmentDavid Mott, ex-CEO of MedImmune and a high-profile biotech partner at New Enterprise Associates, has led the way toward an orphan drug accelerator also backed by Pfizer Ventures. The Cambridge, MA-ba2013/4/12
-
Eli Lilly to lay off hundreds in sales as Cymbalta nears edge of patent cliffHere is a business reality that hundreds of Eli Lilly ($LLY) sales employees are going to have to align themselves with quite soon: They are about to lose their jobs. With its best-selling drug, th2013/4/12
-
Lilly settles long-running lawsuit tying Cymbalta to teen's suicideEli Lilly ($LLY) has battled to protect its best-selling drug, the antidepressant Cymbalta, against generic competition but has decided not to stand and fight a lawsuit tying it to the suicide of a 12013/4/11
-
Vivus investor says FDA move on Qsymia isn't enoughAt least one Vivus ($VVUS) shareholder isn't convinced that loosening FDA restrictions on a new obesity pill will fuel sales in any significant way. First Manhattan, which owns a 9.1% stake in the dr2013/4/11
-
FDA approves morning-sickness drug withdrawn in 1980s safety scareThe FDA has resurrected a morning-sickness treatment that went not-so-gently into the good night 30 years ago, on unfounded worries about birth defects. Diclegis, a tablet made by Canadian-based Duche2013/4/10
-
J&J releases more Doxil to the marketJohnson & Johnson ($JNJ) and the FDA sprang into action in 2011 when J&J's popular chemo drugDoxilbecame hard to get because of problems with the contract manufacturer. While the FDA looked fo2013/4/10